To the Editor:

We appreciate the interest in our article¹ on the safety of topical non-steroidal antiinflammatory drugs (NSAID) in older adults with osteoarthritis (OA). Based on our comprehensive review of the literature (from 1950 through November 2009), we concluded that topical NSAID users do report non-life-threatening gastrointestinal (GI) adverse effects, a greater number of application site reactions, and, importantly, fewer serious GI adverse effects as compared with users of oral NSAID. Altman identifies 2 randomized controlled trials^{2,3} and 2 meeting abstracts^{4,5} that have been published and presented since we conducted our review of the literature.

The 4 referenced studies evaluated the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus placebo vehicle for the treatment of OA. Both published reports^{2,3} were 12-week randomized, double-blind, vehicle-controlled trials evaluating adults aged ≥ 35 years with symptomatic knee OA. Both studies reported that application site dermatitis was more common with DSG than with vehicle: 4.3% versus 1.7%³ and 5.8% versus 0%. As indicated in Altman's letter, both RCT reported a similar range of GI adverse effects (none serious) between DSG and vehicle. Lastly, the range of participants who discontinued the medication due to adverse effects was 5.1%–6.7% in the DSG arm and 1.4%–3.8% in the vehicle arm^{2,3}. These RCT provide us with additional data about the safety of DSG compared to placebo vehicle, and suggest that DSG has fewer application site reactions and a lower withdrawal rate due to adverse effects than another topical NSAID preparation, diclofenac sodium in dimethyl sulfoxide solution (D-DMSO). The RCT do not, however, provide direct evidence of efficacy or safety of topical compared with oral NSAID.

The abstract that was available for review⁵ used a post-hoc analysis of pooled data from 3 similar 12-week, randomized, double-blind, parallel-group, multicenter trials to evaluate the safety of DSG versus placebo vehicle in patients (age ≥ 35 years) with symptomatic knee OA and comorbidities (hypertension, diabetes, and cardiovascular disease). This abstract would not have qualified for inclusion into our systematic review as there was no mention of age distribution (specifically, mean age ≥ 60 years). Based on pooled data, application site dermatitis was again reported more frequently in the DSG arm (5.1%) compared with the vehicle arm (0.6%). GI adverse effects were not listed in the table for "most frequent treatment emergent adverse effects (occurring in $\geq 3\%$ of randomized patients in either group)." The higher rate of discontinuations due to adverse effects with DSG (5.4%) compared with vehicle (2.6%) was attributed to the higher rate of discontinuations due to application site reactions with DSG than with vehicle. The other referenced abstract⁴ was not available for review.

Our systematic review focused on the safety of topical NSAID; however, efficacy of the medication must be weighed against potential adverse effects when making a therapeutic recommendation. Altman highlights the Osteoarthritis Research Society International guidelines⁶ that list a pooled effect size for pain relief of knee and hip OA of 0.29 and 0.44 for oral and topical NSAID, respectively. Efficacy effect sizes of only the high quality trials (Jadad = 5) for oral and topical NSAID are listed as 0.39 and 0.42, respectively. Lin and colleagues⁷ presented a funnel plot with significant asymmetry in the 11 RCT comparing topical NSAID to placebo; this was corroborated by Zhang and colleagues⁶ using 3 additional RCT. As suggested by these authors, the superior effect size of topical NSAID is likely

overestimated due to publication bias from an underreporting of negative studies^{6,7}. Based on the current literature, topical NSAID are comparable to or somewhat less effective than their oral counterparts. Despite this, prior studies have shown that older adults with OA may prefer safer medications even if they are less effective⁸.

It is clear that topical NSAID users report fewer serious GI adverse effects; however, they do report more application site reactions as compared with those who use oral NSAID. It is the responsibility of the health-care provider to discuss the risks and benefits of these treatment options with older patients, since non-life-threatening systemic adverse effects and application site reactions do occur with topical NSAID, and contribute to the tolerability and compliance of this alternative treatment option.

UNA MAKRIS, MD; MINNA KOHLER, MD; LIANA FRAENKEL, MD,
Department of Rheumatology, Yale University School of Medicine, PO
Box 208031, 300 Cedar Street, S-525 TAC, New Haven, Connecticut
06520-8031, USA. Address correspondence to Dr. Makris;
E-mail: una.makris@yale.edu

REFERENCES

1. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: A systematic literature review. *J Rheumatol* 2010;37:1236-43.
2. Baraf HS, Gold M, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: A randomized controlled trial. *Phys Sportsmed* 2010;38:19-28.
3. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. *Semin Arthritis Rheum* 2009;39:203-12.
4. Barthel HR, Petruschke RA, Gold MS, Wieman MS. Safety of diclofenac sodium 1% gel for knee osteoarthritis in patients aged ≥ 65 years with comorbidities. *American Medical Directors Association Long Term Care Medicine* 2010, March 11-14, 2010; Long Beach, CA.
5. Gloth FM, Petruschke RA, Gold MS, Wieman MS. Safety and efficacy of diclofenac sodium 1% gel for knee osteoarthritis in patients with comorbidities [poster]. *American Pain Society Annual Scientific Meeting*, May 6-8, 2010; Baltimore, MD.
6. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARS recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage* 2010;18:476-99.
7. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. *BMJ* 2004;329:324-6.
8. Fraenkel L, Wittink DR, Concato J, Fried T. Informed choice and the widespread use of antiinflammatory drugs. *Arthritis Rheum* 2004;51:210-4.

J Rheumatol 2011;38:3; doi:10.3899/jrheum.100978